DDInter1036 DDInter832
Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. These receptor tyrosine kinases (RTKs) located in the cell membrane play a central role in the activation of signal transduction pathways involved in the normal regulation of cellular processes, such as cell proliferation, migration, apoptosis and differentiation, and in pathogenic angiogenesis, lymphogenesis, tumour
A trihydroxy sugar alcohol that is an intermediate in carbohydrate and lipid metabolism.
Lenvatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Lenvatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Venlafaxine
Lenvatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tipiracil
Lenvatinib {u} may lead to a major life threatening interaction when taken with {v} Vandetanib
Lenvatinib {u} may lead to a major life threatening interaction when taken with {v} Ivosidenib
Lenvatinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Lenvatinib may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine
Lenvatinib may cause a moderate interaction that could exacerbate diseases when taken with Tipiracil
Lenvatinib may lead to a major life threatening interaction when taken with Vandetanib
Lenvatinib may lead to a major life threatening interaction when taken with Ivosidenib